Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)
      QxMD      Google Scholar   
Citation:
Pharmacogenomics J vol 24 (2)
Year:
2024
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
2145   2448  
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
Genentech  
Grants:
U10CA180821, U10CA180882, U24CA196171, UG1CA233253, UG1CA233196, UG1CA233270, UG1CA233290, UG1CA233320, UG1CA233327, UG1CA233341, (PGRN) GM61390, U01GM61393, (NINR) P30NR014129, U10CA180820 (ECOG-ACRIN)  
Corr. Author:
 
Authors:
                                         
Networks:
CA824, LAPS-IL036, LAPS-IL057, LAPS-MD017, LAPS-MN026, LAPS-NC007, LAPS-NY016, NC002   
Study
CALGB-90401
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Genetic association study, Risk factors